Brief: UCB Announces Late-Breaking 2 Year Data For Bimekizumab In HS

UCB SA

27/09/2024 06:05

Sept 27 (Reuters) - Ucb SA  UCB.BR :
    * ANNOUNCES LATE-BREAKING TWO-YEAR DATA FOR
BIMZELX(BIMEKIZUMAB)
IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA AT EADV 2024
    * CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED WITH
BIMEKIZUMAB
OVER ONE YEAR OF TREATMENT WERE MAINTAINED UP TO TWO YEARS (WEEK
96)
    * CLINICALLY MEANINGFUL IMPROVEMENTS OBSERVED WITH
BIMEKIZUMAB
OVER ONE YEAR OF TREATMENT WERE MAINTAINED UP TO TWO YEARS (WEEK
96)
    * APPROXIMATELY ONE IN THREE PATIENTS TREATED WITH
BIMEKIZUMAB
REPORTED MINIMAL OR NO IMPACT OF DISEASE ON THEIR HEALTH-RELATED
QUALITY OF LIFE OVER TWO YEARS
    * UCB SA - AT WEEK 96, OVER EIGHT IN 10 PATIENTS TREATED
WITH
BIMEKIZUMAB ACHIEVED HISCR50, OVER SEVEN IN 10 ACHIEVED HISCR75,
AND OVER FOUR IN 10 ACHIEVED HISCR100

Further company coverage:  UCB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))